to rapidly discover and develop potent, orally available, small molecule inhibitors of the main protease (Mpro) of SARS-CoV-2 using artificial intelligence-driven structure guided drug design

Grant number: INV-031996

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2021
  • Known Financial Commitments (USD)

    $767,100
  • Funder

    Gates Foundation
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    Exscientia AI Limited
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    N/A

Abstract

N/A